New data from a study led by researchers from the University of Minnesota Medical School could change how future antimicrobial drug combinations are discovered and developed.
Trimethoprim-sulfamethoxazole is a highly synergistic antimicrobial drug combination that is widely used to treat a variety of bacterial and fungal infections. These drugs are known to act by targeting specific steps in the folate biosynthetic pathway, and their combined activity is far greater than the sum of their individual activities. For the last fifty years it has been presumed that the basis for their synergistic antimicrobial activity was fairly simple--essentially, that the drugs work together by inhibiting sequential steps in a linear biosynthetic pathway.
A new study from Yusuke Minato, PhD, and Anthony D. Baughn, PhD, from the Department of Microbiology and Immunology at the University of Minnesota Medical School, demonstrates that there is an unrecognized cyclic pathway structure within the folate biosynthesis pathway, the target of these drugs, that allows each drug to enhance the activity of the other.
"We now understand how these two antibiotics work together. An overlooked loop structure of the folate biosynthetic pathway is crucial to produce synergistic activity of these two antibiotics," said Minato.
This discovery, recently published as a paper, "Mutual potentiation drives synergy between trimethoprim and sulfamethoxazole" in Nature Communications, has the potential to open new doors for identification of other synergistic drug combinations.
"It tells us the way we can look for other drug combinations that will have similar synergistic activity," said Baughn. "There is a major problem with drug resistance and lack of effective drugs, not just for Escherichia coli where our work was focused, but for pretty much all infectious diseases."
Baughn and Minato hope that the understanding of mechanisms for synergy will lead them and others to more potent drug combinations that can be deployed in the fight against pathogenic microbes as drug resistance becomes increasingly commonplace.
Source: University of Minnesota Medical School
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.